# Nordic Adjuvant IFN Melanoma Trial

> **NCT01259934** · PHASE3 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 855 (actual)

## Conditions studied

- Melanoma
- Adjuvant Therapy

## Interventions

- **DRUG:** Interferon-alpha2b - 1 year
- **DRUG:** Interferon-alpha2b - 2 years

## Key facts

- **NCT ID:** NCT01259934
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-11
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 855 (ACTUAL)
- **Last updated:** 2010-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259934, "Nordic Adjuvant IFN Melanoma Trial". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01259934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*